Engineered Vesicles for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems face challenges with specificity, targeting, delivery to desired sites of action, pharmacokinetics, complex administration procedures, and patient compliance, leading to low safety and efficacy profiles for many drugs.
Innovation Solution
A targeted vesicle drug delivery composition and method using engineered vesicles, such as exosomes, that contain a fusion protein with a targeting moiety and a vesicle protein, allowing for specific targeting and delivery of therapeutic cargo to desired tissues or cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug delivery systems are used, then drugs can be administered to patients, but they suffer from low specificity and poor targeting leading to low safety and efficacy profiles
Solution Approach 1:
The patent applies local quality by engineering vesicles with heterogeneous surface properties - specific targeting moieties are localized on the vesicle surface to bind particular cell types or tissues, while other regions maintain general biocompatibility. This allows the drug delivery system to simultaneously achieve high specificity for target cells and maintain safety for non-target tissues, directly resolving the contradiction between reliability and adaptability.
Solution Approach 2:
The invention uses composite vesicle structures combining multiple functional components: targeting moieties (such as antibodies or ligands), therapeutic cargo, and vesicle membrane materials. This composite approach enables the system to integrate specific targeting capability with controlled drug release and biocompatibility, improving safety and efficacy profiles while maintaining versatility in drug delivery applications.
2Reliability
If drugs are delivered to desired sites with high precision, then efficacy is improved, but administration procedures become complicated and patient compliance decreases
Solution Approach 1:
The engineered vesicles exhibit self-service characteristics by autonomously navigating to target cells through intrinsic targeting moiety-receptor interactions without requiring external guidance systems. The vesicles self-assemble, self-target, and self-release their cargo in response to specific cellular environments, eliminating the need for complex external control mechanisms and simplifying administration procedures while maintaining high delivery accuracy.
Solution Approach 2:
The patent utilizes parameter changes in the biological environment (such as pH changes in endosomes, redox conditions, or enzyme presence) to trigger drug release at the target site. This passive response to physiological parameters eliminates the need for active control systems or complex administration protocols, thereby maintaining high delivery accuracy while improving ease of operation and patient compliance.
3Reliability
If higher doses of drugs are administered to ensure therapeutic effect, then efficacy is improved, but side effects increase
Solution Approach 1:
The targeting moieties on the vesicle surface provide local quality by concentrating the therapeutic effect specifically at the target cell or tissue site. This localized delivery ensures that high doses of drugs achieve therapeutic efficacy at the intended site while minimizing exposure and side effects in non-target organs, effectively resolving the contradiction between therapeutic efficacy and side effect profile.
Data Source
AI summary
The present disclosure relates to compositions and methods for targeting vesicles to specific tissue and cell types. Also disclosed are compositions and methods for delivering therapeutic molecules, including nucleic acids and nucleic acid derivatives, to specific cells or tissues using vesicles with cell and tissue-specific targeting moieties expressed on their surfaces.